StockMarketWire.com - GlaxoSmithKline's ViiV Healthcare joint venture with Pfizer said its two-drug HIV treatment regime had met its primary goals after demonstrating a similar level of efficacy in controlling HIV-1 as a three-drug regimen.

The clinical results showed that individuals who were already on treatment can maintain viral suppression if they switch from a 3-drug, tenofovir alafenamide fumarate (TAF)-containing regimen to a 2-drug regimen of dolutegravir plus lamivudine,' the company said.

The phase III TANGO study was conducted to assess whether adults living with HIV-1 who had maintained viral suppression for at least six months on a tenofovir alafenamide fumarate (TAF)-containing regimen of at least three drugs, were able to maintain similar rates of viral suppression after switching to the 2-drug regimen (2DR) of dolutegravir plus lamivudine in a fixed dose combination, compared to continuing the TAF-containing regimen.

No patients met confirmed virologic withdrawal criteria or developed treatment resistance in the dolutegravir plus lamivudine (two-drug regimen) arm of the study, the company said.




At 8:09am: [LON:GSK] GlaxoSmithKline PLC share price was -6.2p at 1634p



Story provided by StockMarketWire.com